{"id":"NCT01114204","sponsor":"AMAG Pharmaceuticals, Inc.","briefTitle":"A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia","officialTitle":"A Phase III, Randomized, Open-label, Active-Controlled, Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08-10","primaryCompletion":"2011-11-09","completion":"2012-06-25","firstPosted":"2010-05-03","resultsPosted":"2018-06-11","lastUpdate":"2022-04-21"},"enrollment":605,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Iron Deficiency Anemia"],"interventions":[{"type":"DRUG","name":"Ferumoxytol","otherNames":["Feraheme"]},{"type":"DRUG","name":"Iron Sucrose","otherNames":["Venofer"]}],"arms":[{"label":"Ferumoxytol","type":"EXPERIMENTAL"},{"label":"Iron Sucrose","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared to IV iron sucrose for the treatment of iron deficiency anemia (IDA).","primaryOutcome":{"measure":"Participants Who Achieved A â‰¥2.0 g/dL Increase In Hemoglobin At Any Time From Baseline To Week 5","timeFrame":"Baseline (Day 1) through Week 5","effectByArm":[{"arm":"Ferumoxytol","deltaMin":291,"sd":null},{"arm":"Iron Sucrose","deltaMin":117,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2833"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":96,"countries":["Australia","France","Germany","Hungary","Italy","Latvia","Lithuania","Poland","Romania","South Africa","South Korea","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["27462400","24639149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":406},"commonTop":["Headache","Dysgeusia","Nausea","Dizziness","Chest discomfort"]}}